药物撤市对治疗替代药不良事件报告的影响:法国自发报告数据库研究
本研究利用法国药物警戒数据库和保险受益人随机样本,分析右丙氧芬、吡格列酮和四氢西泮因安全原因撤市后,其治疗替代药的不良事件报告变化。结果显示三种药物撤市后,替代药的不良事件报告数增幅均超过处方量增幅,提示可能存在新用药者不良事件发生增加或报告意识提高。
要点
- 右丙氧芬撤市后,曲马多和可待因的报告数增幅超过报销增幅。
- 吡格列酮撤市后,DPP-4抑制剂每万治疗患者报告率显著升高。
- 四氢西泮撤市后,地西泮和硫秋水仙碱每万治疗患者报告率升高。
核心结论
- 三种药物撤市后,替代药的不良事件报告数增幅大于处方量增幅,可能与新用药者不良事件发生增加或报告意识提高有关。
研究设计与样本
- 基于法国药物警戒数据库和Echantillon Généraliste des Bénéficiaires随机样本,比较撤市前一年与撤市后一年的病例报告数和类型。
- 计算每万次报销和每万治疗患者的报告率,并比较两个时期。
主要发现
- 右丙氧芬撤市后,曲马多病例报告增加23%、报销增加13%,可待因病例报告增加74%、报销增加47%。
- 吡格列酮撤市后,DPP-4抑制剂、格列奈类和GLP-1类似物的病例报告分别增加84%、22%和5%,报销分别增加55%、11%和50%。
- 四氢西泮撤市后,地西泮、美索巴莫和硫秋水仙碱的病例报告分别增加110%、86%和157%。
关键数值与推荐
- 右丙氧芬撤市后,曲马多每万治疗患者报告率显著增加(0.92 vs. 1.06,p=0.02)。
- 吡格列酮撤市后,DPP-4抑制剂每万治疗患者报告率显著增加(1.63 vs. 2.26,p=0.008)。
- 四氢西泮撤市后,地西泮每万治疗患者报告率增加(1.78 vs. 2.41,p=0.054),硫秋水仙碱每万治疗患者报告率显著增加(0.14 vs. 0.24,p=0.013)。
临床怎么用
- 药物撤市后,应关注替代药在新用药者中的不良事件报告信号。
- 药物警戒人员需结合处方量变化解读报告率,避免因报告意识提高而误判风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The consequences of the withdrawal of marketing authorisation of drugs have mostly been studied considering drug prescription patterns for the therapeutic alternatives of the withdrawn drugs. The potential concomitant changes in the reporting of adverse reactions concerning these alternatives have been studied less often. OBJECTIVE: The objective of this study was to analyse the changes in the reporting of adverse events (AEs) for therapeutic alternatives after the withdrawal of three medicines (dextropropoxyphene, pioglitazone and tetrazepam) from the market for safety reasons. METHODS: This study was performed using both the French pharmacovigilance database and the Echantillon Généraliste des Bénéficiaires (a random sample of French health insurance affiliates). For dextropropoxyphene, pioglitazone and tetrazepam alternatives, the number and types of case reports were studied for both the year preceding the first official safety warning and the year following the withdrawal. Reporting rates expressed per 10,000 reimbursements (RRReimb) and per 10,000 treated patients (RRPat) were also compared for the two periods. RESULTS: After dextropropoxyphene withdrawal, case reports and reimbursements increased for tramadol (case reports: +23%, reimbursements: +13%) and codeine (case reports: +74%, reimbursements: +47%), RRPat being significantly increased for tramadol (0.92 vs. 1.06, p = 0.02). After pioglitazone withdrawal, case reports increased for dipeptidyl peptidase-4 (DPP-4) inhibitors, glinides, and glucagon-like peptide 1 (GLP-1) analogues (+84%, +22% and +5%, respectively) and reimbursements (+55, +11 and +50%, respectively); both decreased for sulfonylureas (case reports: -6%, reimbursements: -2%). RRPat increased for DPP-4 inhibitors (1.63 vs. 2.26, p = 0.008). After tetrazepam withdrawal, case reports increased for diazepam, methocarbamol and thiocolchicoside (+110, +86 and +157%, respectively), as lesser did reimbursements. RRPat increased for diazepam (1.78 vs. 2.41, p = 0.054) and thiocolchicoside (0.14 vs. 0.24, p = 0.013). CONCLUSION: For the three drug withdrawals investigated, the number of case reports involving alternatives increased to a larger extent than the numbers of prescriptions. This could relate to a higher occurrence of AEs in new users of alternatives who switched from the withdrawn medicines or to an increased awareness of possible AEs.
引用
- Pageot C, Bezin J, Smith A, et al. Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database. Drug Saf. 2017. PMID: 28664354. doi:10.1007/s40264-017-0561-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。